• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why ObsEva Shares Are Trading Higher By Over 70%; Here Are 21 Stocks Moving Premarket

    11/22/22 6:22:00 AM ET
    $ACHV
    $BFRI
    $COSM
    $CYCN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACHV alert in real time by email

    Gainers

    • ObsEva SA (NASDAQ:OBSV) shares rose 71.9% to $0.2848 in pre-market trading after the company reported the sale of Ebopiprant license agreement to XOMA for up to $113 million.
    • Secoo Holding Limited (NASDAQ:SECO) shares rose 24% to $0.3450 in pre-market trading.
    • Cosmos Holdings Inc. (NASDAQ:COSM) rose 17% to $0.2050 in pre-market trading after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on Iberian Airlines' in-flight magazine, Ronda.
    • Gaotu Techedu Inc. (NYSE:GOTU) shares jumped 13.2% to $1.20 in pre-market trading after the company posted a narrower quarterly loss.
    • Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) rose 12.5% to $0.63 in pre-market trading after gaining around 8% on Monday.
    • Nexalin Technology, Inc. (NASDAQ:NXL) rose 12.2% to $2.30 in pre-market trading after surging around 14% on Monday.
    • First Wave BioPharma, Inc. (NASDAQ:FWBI) rose 8.9% to $0.74 in pre-market trading. First Wave BioPharma reported a private placement.
    • Biofrontera Inc. (NASDAQ:BFRI) rose 8.8% to $1.05 in pre-market trading. Biofrontera will launch Phase 3 clinical study evaluating Ameluz-PDT for the treatment of actinic keratosis on the extremities, neck and trunk.
    • Achieve Life Sciences, Inc. (NASDAQ:ACHV) rose 8% to $2.70 in pre-market trading. Achieve Life Sciences recently reported a private placement of $18.9 million.
    • Esports Entertainment Group, Inc. (NASDAQ:GMBL) rose 7.9% to $0.1080 in pre-market trading after declining over 10% on Monday.
    • EUDA Health Holdings Limited (NASDAQ:EUDA) rose 7.1% to $4.05 in pre-market trading after dipping 15% on Monday.


    Don’t forget to check out our premarket coverage here .


    Losers

    • Gamida Cell Ltd. (NASDAQ:GMDA) fell 18% to $1.46 in pre-market trading after the company issued a regulatory update on Omidubicel. The company said it received extension of Omidubicel PDUFA Date from Jan. 30, 2023 to May 1, 2023 as the FDA issued information request.
    • Hillstream BioPharma, Inc. (NASDAQ:HILS) shares fell 14.7% to $0.4004 in pre-market trading after jumping 10% on Monday.
    • Tantech Holdings Ltd (NASDAQ:TANH) shares fell 13.5% to $1.80 in pre-market trading. Tantech Holdings recently announced a 1-for-24 common share consolidation.
    • Zoom Video Communications, Inc. (NASDAQ:ZM) fell 9.2% to $72.81 in pre-market trading after the company reported better-than-expected results, but issued weak guidance.
    • Drive Shack Inc. (NYSE:DS) shares fell 9.1% to $0.4002 in pre-market trading after jumping 23% on Monday. Drive Shack recently reported Q3 EPS and sales results were higher year over year.
    • Venus Concept Inc. (NASDAQ:VERO) shares fell 9% to $0.1820 in pre-market trading after gaining over 10% on Monday. The company recently posted downbeat quarterly sales.
    • Siyata Mobile Inc. (NASDAQ:SYTA) fell 8.8% to $0.1771 in pre-market trading after jumping 26% on Monday.
    • Canoo Inc. (NASDAQ:GOEV) fell 6.9% to $1.08 in pre-market trading. The company recently posted a narrower-than-expected quarterly loss.
    • Meta Materials Inc. (NASDAQ:MMAT) fell 6.4% to $2.02 in pre-market trading after jumping 30% on Monday. Meta Materials recently posted a Q3 loss of $0.07 per share.
    • Eqonex Limited (NASDAQ:EQOS) fell 6.3% to $0.1965 in pre-market trading after dipping around 24% on Monday.
    Get the next $ACHV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHV
    $BFRI
    $COSM
    $CYCN

    CompanyDatePrice TargetRatingAnalyst
    Achieve Life Sciences Inc.
    $ACHV
    4/21/2026$13.00Buy
    Canaccord Genuity
    Zoom Communications Inc.
    $ZM
    2/5/2026$115.00Peer Perform → Outperform
    Wolfe Research
    Zoom Communications Inc.
    $ZM
    1/12/2026$106.00Neutral → Buy
    Citigroup
    Zoom Communications Inc.
    $ZM
    12/17/2025$105.00Buy
    BTIG Research
    Achieve Life Sciences Inc.
    $ACHV
    11/25/2025$19.00Mkt Outperform
    Citizens JMP
    Zoom Communications Inc.
    $ZM
    10/21/2025$85.00Equal-Weight
    Morgan Stanley
    Zoom Communications Inc.
    $ZM
    10/20/2025$85.00Neutral
    UBS
    Achieve Life Sciences Inc.
    $ACHV
    8/21/2025$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACHV
    $BFRI
    $COSM
    $CYCN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

    For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

    4/17/23 1:02:15 PM ET
    $GMDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Goldberg Andrew D.

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    4/21/26 6:20:25 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Goldberg Andrew D.

    3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    4/21/26 6:16:43 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Bawa Aparna

    4 - Zoom Communications, Inc. (0001585521) (Issuer)

    4/21/26 4:54:01 PM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    $ACHV
    $BFRI
    $COSM
    $CYCN
    SEC Filings

    View All

    SEC Form 20-F filed by Gaotu Techedu Inc.

    20-F - Gaotu Techedu Inc. (0001768259) (Filer)

    4/22/26 6:08:04 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    SEC Form S-4 filed by Cyclerion Therapeutics Inc.

    S-4 - Cyclerion Therapeutics, Inc. (0001755237) (Filer)

    4/17/26 9:46:26 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Achieve Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

    4/16/26 4:47:39 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Buy Research Opinion on Zoom Communications (NASDAQ: ZM)

    NOTE TO EDITORS: The Following Is an Investment Opinion Issued by Spruce Point Capital Management Provides Evidence the Bear Thesis on Zoom Shares Does Not Hold Up to Scrutiny Believes Zoom's Transformation Into a Comprehensive, Value-Added, AI-First Platform Poised to Drive Deeper Enterprise Penetration is Underappreciated Demonstrates Zoom is Trading at a Massive Discount to Its Intrinsic Value, Particularly Considering Its Share Ownership in AI Leader Anthropic Identifies A Range of Cost Structure, Organizational Effectiveness, Capital Allocation Practices, and Corporate Governance Concerns For Zoom to Address Announces It Has Sent the Zoom Board of Directors a Letter Containin

    4/24/26 8:30:00 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    Gaotu Techedu Files Its Annual Report on Form 20-F

    BEIJING, April 22, 2026 /PRNewswire/ -- Gaotu Techedu Inc. (NYSE:GOTU) ("Gaotu" or the "Company"), a leading technology-driven education company in China focused on enabling lifelong learning through AI-powered solutions, today filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission. The annual report on Form 20-F can be accessed on the Company's investor relations website at https://ir.gaotu.cn/. The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Investor Rel

    4/22/26 6:25:00 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

    Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors  New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone Warrants), Strengthen Achieve's Position to Execute Development and Launch of Cytisinicline, if Approved, as the First New Treatment for Nicotine Dependence in Two Decades SEATTLE and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) today announced it has appointed Andrew D. Goldberg, MD, as Chief Executive Officer and as a member of the Board of Directors, effective following the closing of Achieve's recently announced financing

    4/16/26 8:57:06 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Achieve Life Sciences with a new price target

    Canaccord Genuity initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $13.00

    4/21/26 7:30:27 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Zoom Communications upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Zoom Communications from Peer Perform to Outperform and set a new price target of $115.00

    2/5/26 6:52:31 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    Zoom Communications upgraded by Citigroup with a new price target

    Citigroup upgraded Zoom Communications from Neutral to Buy and set a new price target of $106.00

    1/12/26 7:53:13 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Financials

    Live finance-specific insights

    View All

    Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Buy Research Opinion on Zoom Communications (NASDAQ: ZM)

    NOTE TO EDITORS: The Following Is an Investment Opinion Issued by Spruce Point Capital Management Provides Evidence the Bear Thesis on Zoom Shares Does Not Hold Up to Scrutiny Believes Zoom's Transformation Into a Comprehensive, Value-Added, AI-First Platform Poised to Drive Deeper Enterprise Penetration is Underappreciated Demonstrates Zoom is Trading at a Massive Discount to Its Intrinsic Value, Particularly Considering Its Share Ownership in AI Leader Anthropic Identifies A Range of Cost Structure, Organizational Effectiveness, Capital Allocation Practices, and Corporate Governance Concerns For Zoom to Address Announces It Has Sent the Zoom Board of Directors a Letter Containin

    4/24/26 8:30:00 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

    Combined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases Korsana's lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer's disease Concurrent private financing of approximately $380 million expected to fund Korsana's operations into 2029, including multiple clinical trial data readouts expected in 2027 Conference call scheduled for April 1, 2026, at 8:00 am ET Cyclerion Therapeutics, Inc. ("Cyclerion") (NASDAQ:CYCN) and Korsana Biosciences, Inc. ("Korsana"), a privately-held biotechnology company discovering and developin

    4/1/26 7:05:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced financial results for the fourth quarter and full year 2025 and provided updates on the cytisinicline development program, including the announcement of its partnership with Adare Pharma Solutions (Adare). "Achieve is full

    3/24/26 7:00:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gaotu Techedu Inc.

    SC 13G/A - Gaotu Techedu Inc. (0001768259) (Subject)

    11/27/24 6:02:40 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Siyata Mobile Inc.

    SC 13G/A - Siyata Mobile Inc. (0001649009) (Subject)

    11/14/24 7:28:44 PM ET
    $SYTA
    Telecommunications Equipment
    Telecommunications

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ACHV
    $BFRI
    $COSM
    $CYCN
    Leadership Updates

    Live Leadership Updates

    View All

    Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

    Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors  New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone Warrants), Strengthen Achieve's Position to Execute Development and Launch of Cytisinicline, if Approved, as the First New Treatment for Nicotine Dependence in Two Decades SEATTLE and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) today announced it has appointed Andrew D. Goldberg, MD, as Chief Executive Officer and as a member of the Board of Directors, effective following the closing of Achieve's recently announced financing

    4/16/26 8:57:06 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Announces Up to $354 Million Private Placement

    $180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors and Marshall Wace SEATTLE, Wash. and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities for

    4/16/26 8:53:49 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Zoom appoints Russell Dicker as chief product officer to advance AI-first product strategy and workflow automation

    SAN JOSE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Zoom Communications, Inc. (NASDAQ:ZM) today announced the appointment of Russell Dicker as the company's chief product officer (CPO), leading product strategy for Zoom's system of action, turning conversations into completed work through AI. Russell brings more than 25 years of experience building and scaling global product platforms, including leading Microsoft Teams' product and data science teams, with a focus on applying AI to simplify workflows and improve how work gets done. Russell joins Zoom at a pivotal time, as companies seek AI tools to automate processes and tasks, freeing up time for higher-level work. Zoom is uniquely posi

    4/15/26 9:05:00 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology